Samsung BioLogics applies for listing review

[THE INVESTOR] Samsung BioLogics on Aug. 12 applied to the Korea Exchange for a preliminary listing review.

The world’s third largest biologics contract manufacturer by capacity will be the first pharmaceutical firm to be listed on the benchmark KOPSI in 10 years.

The company is 51 percent held by Samsung C&T, and 46.8 percent by Samsung Electronics. 

A screen welcoming visitors to Samsung BioLogics/ The Investor

Samsung BioLogics is expected to be the largest IPO this year. The industry estimates subscription of about 3 trillion won (US$2.72 billion), with the firm’s market capitalization likely to exceed 10 trillion won.

According to reports, the firm plans to use the capital raised through the IPO to increase its annual production capacity to 360,000 liters by 2018. Its current production capacity stands at 180,000 liters.

Last year, the company posted revenue of 91.3 billion won, and net profit of about 1.9 trillion won.

By Choi He-suk (cheesuk@heraldcorp.com)